You searched for "therapeutics"

378 results found

New study uncovers key mechanism behind a common genetic cause of age-related visual loss

A groundbreaking study has revealed important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, providing hope for future therapeutic developments, and finding implications for other neurological diseases. FECD is a common,...

Amblyopia treatment review

This review paper summarises the main causes and neural mechanisms that characterise amblyopia. The authors analysed neuroanatomical, neurophysiological and electrophysiological studies in the literature to better understand actual treatment regimens and evaluate new therapeutic possibilities. They considered causes of strabismus,...

Developments in Ophthalmology: Ophthalmic Radiation Therapy Techniques and Applications

Radiation was discovered by Wilhelm Roentgen in 1895, and since then has been used to treat a variety of cancers. Its therapeutic properties have been widely used for ocular and periocular tumours and inflammatory disease, but the present era is...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...

Moorfields: Ocular emergencies level 1

Designed for optometrists, orthoptists, nurses and other allied ophthalmic health professionals, this module will deliver the knowledge and skills required for the examination, investigation, diagnosis, treatment, and management of patients who present in an ophthalmic emergency setting. Entry requirementsBSc (Hons)...

Conference Report: Retina UK 2025

The Retina UK Annual Conference 2025 took place at the Holiday Inn London in London, UK, on 20 September and was hosted both in-person and online. The event included expert speakers, healthcare professionals, and patients with lived experience with retinal...

Effect of the COVID-19 Urgent Eyecare Service on patient referrals to general practitioners and Hospital Eye Service

The COVID-19 Urgent Eyecare Services (CUES) was developed to relieve the demands of hospital ophthalmology, aiming to allow patients to have remote consultations and be managed by community optometric practice. This was because access to Hospital Eye Service (HES) Ophthalmic...

My Top Five: Promising gene therapies for ocular conditions

Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...

My Top Five: Promising gene therapies for ocular conditions

Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...

Platelet rich fibrin membrane for descemetocele

This case series described the use of a novel technique in the treatment of descemetocele. Three patients developed descemetoceles following infective keratitis with impending risk of corneal perforation. Platelet rich fibrin (PRF) membrane was prepared using 8ml of fresh venous...

DALK as an early therapeutic option for Acanthamoeba keratitis

Eleven patients with Acanthamoeba keratitis (AK) were treated by early therapeutic deep anterior lamellar keratoplasty (DALK). All surgeries were performed in patients who had no response to standard medical therapy of chlorhexidine gluconate, propamidine isethionate and neomycin sulphate, within 10-15...

Ranibizumab for the treatment of age-related macular degeneration

This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12...